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Edited by Jesus AvilaAbstract Misfolded prion protein, PrPSc, is believed to be the
pathogenic agens in transmissible spongiform encephalopathies.
Little is known about the autocatalytic misfolding process.
Looking at the intrinsic properties of short sequence stretches,
such as conformational ﬂexibility and the tendency to populate
extended conformers, we have examined the aggregation behav-
iour of various peptides within the region 106–157 of the se-
quence of human prion protein. We observed fast aggregation
for the peptide containing residues I138-I-H-F141. This se-
quence, which is presented at the surface of cellular prion pro-
tein, PrPC, in an almost b-sheet-like conformation, is therefore
an ideal anchor-point for initial intermolecular contacts leading
to oligomerization. We further report that the aggregation pro-
pensity of the neurotoxic peptide 106–126 appears to be centred
in its termini and not in the central, alanine-rich sequence (A113-
G-AAAA-G-A120).
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Transmissible spongiforme encephalopathies (TSEs) are a
group of fatal neurodegenerative disorders leading to a large
scale loss of neurons in the central nervous system. They aﬀect
man (CJD, FFI, GSS) and various animals (bovine spongi-
forme encephalopathy, scrapie, chronic wasting syndrome).
According to the protein-only hypothesis [1], these diseases
are caused by the conformational transition of the cellular
prion protein, PrPC, into the misfolded isoform PrPSc. Human
PrPC is a soluble cell surface glycoprotein of 231 residues, con-
sisting of an unstructured amino-terminal domain and a
mostly a-helical carboxy-terminal domain [2]. Its physiological
function is not fully understood at the moment, but evidence
points to an involvement in various cellular processes, suchAbbreviations: PrP, prion protein; TSE, transmissible spongiforme
encephalopathies; CJD, Creutzfeldt-Jakob disease; FFI, fatal familial
insomnia; GSS, Gerstmann–Stra¨ussler–Scheinker syndrome; EM,
electron microscopy; CR, Congo Red; PPII, poly-proline II
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doi:10.1016/j.febslet.2006.03.002as regulation of presynaptic copper levels [3] and protection
from oxidative stress [4], as well as several signal transduction
pathways [5–7].
In contrast to the cellular prion protein, PrPSc is predomi-
nantly b-sheet, resistant to protease K, has a low solubility
in non-denaturing solvents and aggregates readily into amy-
loid-like ﬁbrils [1,8]. Recently, Wille et al. proposed a ﬁrst
structural model of PrPSc based on electron crystallography
data with a resolution of about 7 A˚ [9,10]. According to this
model, PrPSc adopts a b-helical structure, which incorporates
the unstructured amino terminus as well as helix 1 and the
short antiparallel b-sheet of PrPC, while the disulﬁde-linked
helices 2 and 3 retain their helical conformation.
Though the mechanism and initiation site of the prion con-
formational conversion is not known, it could be shown that
only part of the PrPC sequence is needed for the transconfor-
mation and the formation of amyloid ﬁbrils [11]. Several short
peptides derived from the amino-terminal region of the globu-
lar domain of PrP are known to aggregate in solution and ex-
hibit cytotoxic properties. One major amyloidogenic sequence
spanning residues 106–126 in human PrP contains the highly
conserved, apolar AGAAAAGA palindrome [12]. In addition,
amyloid formation could be observed for the sequences huPrP
(106–147) [13], huPrP (118–135) [14], huPrP (132–160) and
huPrP (124–167) [15]. All of these peptides fulﬁl one major cri-
terion for amyloid formation, namely the adoption of unstruc-
tured or partially unstructured conformations [16].
Though amyloid formation may be a general property of
polypeptides [17], the initiation of peptide aggregation is
dependent on the presence of short sequence stretches which
follow certain general rules [18], as well as on the absence of
‘‘gatekeeper’’ residues preventing b-sheet formation [19]. In
particular, the presence of sequences composed of bulky, steri-
cally restricted amino acid residues, which have been shown to
display an intrinsic preference for extended, b-sheet like con-
formations in the random coil state by analysis of sequence
corrected NMR chemical shifts [20], is supposed to enhance
the ﬁbril formation tendency of peptides. On the other hand,
clusters of small amino acids, such as alanine or glycine, have
backbone mobility much higher than an average random coil
sequence [20]. Such clusters may be assumed to probe a large
number of conformations in the Ramachandran plot on a very
fast time scale minimizing the life time of individual, aggrega-
tion prone conformations.
As a consequence, even point mutations can dramatically
alter the aggregation behaviour of proteins [21]. Because
the pathogenic prion-conversion is likely to involve large-
scale rearrangement of tertiary structure – as implied by
the structures of PrPC [2] and the model of Govaertsblished by Elsevier B.V. All rights reserved.
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partially unfolded intermediates are signiﬁcantly populated
during prion conversion. To obtain further insights into
the mechanistic details of PrPSc formation, it is therefore
of interest to investigate structural preferences in the random
coil state of the corresponding sequence. Here, we perform a
turbidimetric analysis of the aggregation behaviour of a ser-
ies of overlapping peptides spanning residues 106–157 of hu-
man prion protein, which have been selected on the basis of
pre-existing data on their conformational behaviour in the
random coil state, to detect possible initiation sites for inter-
molecular aggregation. This sequence is largely identical to
the interaction interface between heterologous forms of the
prion protein, underscoring the importance to investigate
in particular this sequence [22].2. Materials and methods
2.1. Peptide design
Peptides for this study were selected to include diﬀerent combina-
tions of putative aggregation initiation sites, such as the apolar palin-
drome A113-GAAAAGA, b-sheet 1 (128–131), the sequence I138-IHF
and the putative gatekeeper element helix 1 (144–154). Stabilizing
(N153W) and destabilizing (R151G) mutants of PrP helix 1 were de-
signed employing in-house written software [23]. To facilitate spectro-
photometric determination of peptide concentrations, a tyrosine
residue was added to the amino-terminus of peptides lacking tyrosine
in their sequence.2.2. Peptides
Peptides were purchased from Jerini AG (Berlin, Germany) and
from Thermo Electron Corporation (Ulm, Germany) as HPLC-puri-
ﬁed freeze dried powder containing triﬂuoroacetate counter ions. Pep-
tides were protected by an amino-terminal acetyl group and by
amidation at the carboxy-terminus to exclude charge eﬀects from free
termini. The sequences of the peptides under investigation are summa-
rized in Fig. 1.2.3. Aggregation tests
Buﬀer conditions applied here were optimized prior to this study
with respect to lag-time and duration of transitions. Peptides were dis-
solved in 20 mM sodium acetate buﬀer containing 20% DMSO p.a.
(Sigma–Aldrich, St. Louis, MO, USA) and 0.01% sodium azide to pre-
vent bacterial growth (Fluka, Switzerland), pH 4.5, sonicated three
times for 5 min each, centrifuged at 14000 · g for 1 h, and stored as
frozen stocks at 20 C. After UV spectrophotometric determination
of concentration using an emM (280 nm) of 1.28 mM
1 cm1 (http://
www.expasy.org/tools/protparam.html), all peptide samples were ad-
justed to a concentration of 50 lM, except for peptides encompassing
helix 1. Initial absorptions in the samples were 0.0073 AU per residue
with a standard deviation of 0.0026 AU. This small scatter – compared
to the increases in absorbance measured in sigmoidal transitions upon
aggregation – indicates the absence of aggregates at the beginning of
measurements. Concentrations of helix 1 peptides were higher in order
to be able to observe any transition (huPrP(140–158): 106 lM,
huPrP(140–158)N153W: 94 lM; huPrP(140–158)R151G: 82 lM).
Higher concentrations were not possible due to the limited solubility
of selected peptides. To follow the time course of aggregation, the tur-
bidity at 450 nm was measured every 3–6 h on an Uvikon 930 spectro-
photometer (Kontron Instruments, Eching, Germany) for a total of
180 h in sealed 70 ll microcuvettes (Brand, Wertheim, Germany) to
prevent volume- and concentration-changes due to solvent evapora-
tion. Prior to each measurement samples were homogenized by careful
agitation. Between measurements samples were stored at 23 C. An
identical cuvette ﬁlled with buﬀer without any peptide treated exactly
as the samples was used a reference in turbidity measurements. Before
each measurement, the photometer was zeroed using a cuvette with
peptide free buﬀer solution.2.4. Data evaluation
In order to obtain an estimate of the aggregation tendencies of the
peptides, we have determined the approximate lag-time, the apparent
rate of aggregation, and the midpoint of the aggregation transition.
Lag-time was deﬁned as the duration of approximately linear behav-
iour of the turbidimetric data and was determined by visual inspection.
The approximate lag-time reported corresponds to the last data point
prior to the aggregation transition. Assuming exponential growth data
points past the lag-time were ﬁt to an exponential growth function
A450 ¼ Alag-timeþ1450 þ Bð1 ektÞ
where Alag-timeþ1450 represents the ﬁrst data point past the approximate
lag-time, B the parameter corresponding to the signal amplitude, and
t the time in hours. k was taken as the apparent rate of aggregation.
The midpoint of the aggregation transition, taggr was obtained by sub-
tracting the approximate lag-time from the midpoint of the sigmoidal
transition tm. tm was obtained by ﬁtting the observed data to the sig-
moid function
A450 ¼ At¼0450 þ
DA450
1þ ettmb
where DA450 represents the diﬀerence in turbidity between the initial
and the ﬁnal equilibrium state, giving a measure for the extent of
aggregation, t denotes the time in hours, and b represents the width
of the sigmoidal transition. Fitting was performed using the program
SigmaPlot 2001 (SPSS Inc., Chicago, IL, USA).
2.5. Whole mount electron microscopy
Samples from turbidity assays were stored for additional three weeks
at 4 C to allow ﬁbril formation to complete. For whole mount elec-
tron microscope (EM) samples were spun down at 18000 · g for 1 h.
Five microlitres from each tube were applied to a pioloform-coated
copper grid (Plano GmbH, Marburg, Germany) and allowed to adhere
for 10 min. The grids were stained with 1% aqueous uranyl acetate for
1–2 min. Samples were examined in a Zeiss 902A transmission electron
microscope (Carl Zeiss, Oberkochen, Germany) operated at 80 kV.
Micrographs were taken using SO-163 EM ﬁlm (Kodak, Rochester,
NY).
2.6. Congo Red (CR) staining
CR staining of ﬁbril preparations was performed in a variation of
Puchtler’s method after turbidity measurements. Fibril containing
samples were centrifuged at 10000 · g for 30 min, the pellets were sus-
pended to HistoBond slides and allowed to dry at 50 C. The dried
samples were stained with saturated CR solution in 80% ethanol con-
taining 1 M NaCl for 20 min. Unbound CR was removed by washing
in distilled water followed by rinsing with 80% ethanol. The stained
and dried samples were subsequently embedded in gummi arabicum
and visually inspected for birefringence under a polarization micro-
scope (B1-220, MOTIC, Wetzlar, Germany) equipped with a SLR
camera (Canon 350-D, Japan. Note. The colours seen are slightly dis-
torted due to the inability to perform correct white balance with the
camera mounted to the microscope; pictures were only c-corrected
to avoid further distortions of colour).
2.7. Calculation of aggregation propensities
Theoretical calculations of aggregation propensities of various pep-
tide sequences and the inﬂuence of selected residues within these se-
quences have been carried out with the software TANGO (http://
tango.embl.de) at a pH of 4.5 [24,25].3. Results and discussion
The aim of this study was to determine possible or likely ini-
tiation regions of prion amyloid formation. Though there are
several publications describing the aggregation behaviour of
peptides encompassing the amino terminal region of the glob-
ular prion domain [12–15,26], the diﬀerences in conditions ap-
plied in theses studies make it diﬃcult to assess relative
Fig. 1. (A) Structure of huPrP(121–231) [2]. The partially solvent exposed sequence of hydrophobic residues I138-IHF is shown as dark gray sticks.
(B) Schematic overview over the amino acid sequence of huPrP(106–158) and the peptides used in this study . The secondary structure representation
shows structural elements derived from the NMR structure [2]. Putative aggregation sites are printed italic underlined, the putative gatekeeper
element a-helix 1 and b-strand 1 are printed bold. The positions of the designed stabilizing (N153W) and destabilizing (R151G) mutations are also
indicated [23].
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data set for the whole 106–157 region we performed turbidi-
metric aggregation assays on a series of overlapping peptides
corresponding to this sequence. Turbidimetry is a rapidly
available assay for the qualitative description of an aggrega-
tion process, which does not allow the determination of the
aggregates size such as light scattering methods do. The appli-
cation of the latter, however, is limited in the case of small pep-
tides at very low concentrations. The peptides were chosen to
encompass all structural elements present in this region, as well
as all known functionally important sequences, like the cyto-
toxic palindrome and the regions important for the species
barrier. A set of peptides with comparable lengths
(huPrP(110–120), huPrP(128–136), huPrP(137–145)) was cho-
sen to allow easy comparison of aggregation parameters for
the diﬀerent structural and functional elements. Additional
peptides were introduced into the study to allow the investiga-
tion of eﬀects of ﬂanking sequences (see Fig. 1).
All investigated peptides adopt a random coil conformation
in their soluble monomeric state, with the exception of the
145–155 region (helix 1 in the structure of the full length prionprotein), which shows a tendency to populate helical confor-
mations in isolated peptides [27]. The key parameters of the
measured peptide aggregation are summarized in Table 1
(apparent aggregation rate k, tm, taggr, lag-time, DA450). In re-
peated measurements of several samples which were prepared
under apparently identical conditions, outliers with a markedly
faster aggregation could be observed in several series. How-
ever, the majority of measurements showed consistent experi-
mental values. A similar phenomenon has been reported in a
recent study by Hortschansky et al., who investigated several
derivatives of the Ab peptides and found large deviations of
transition midpoints and rates for apparently identical samples
[28]. In this report the amount of scatter as well as the lag-time
correlate with the peptide concentration: less peptide results in
larger scatter and longer lag-times. The authors conclude that
even under strongly controlled experimental conditions, pep-
tide polymerization reactions are highly inﬂuenced by stochas-
tic factors. In the present study, the peptide concentration
could not be further increased. However, the relative aggrega-
tion tendencies reported could be reproduced in independent
measurements (data not shown).
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aggregation propensity than b-strand 1 (see Table 1)
huPrP(128–136), which includes b-strand 1 and which was
used here as paradigmatic model for b-strand self-association,
showed a clear transition with a taggr of 28 h and an average
apparent rate k of 0.024 h1. The diﬀerence in absorbance
was between 0.1 and 0.15 AU. Such a clear transition was ex-
pected as single b-strands have a well-known tendency for self-
association. huPrP(137–145), which corresponds to the loop
between b-strand 1 and helix 1, displayed a much faster course
of aggregation with a taggr of approximately 7–8 h and an
apparent rate k of 0.15 h1 and a slightly reduced approximate
lag-time. Both peptides are of the same length, and each of
them contains one possible initiation site for aggregate forma-
tion: b-strand 1, which is part of the huPrP(128–136) peptide,
has been implicated in ﬁbril formation in studies on the peptide
huPrP(118–135). huPrP(137–145) contains a region of bulky
apolar residues immediately preceding helix 1 (I138-IHF),
which showed a tendency to adopt extended conformations
in NMR studies of peptides containing the helix 1 region of
huPrP [27]. While huPrP(128–135) shows ﬁne ﬁbrillar aggre-
gates, the aggregates of huPrP(137–145) appear to be highly
ordered, in a nearly crystalline structure (see Fig. 2).
Despite being experimentally identiﬁed as a putative aggre-
gation association site, this sequence is not detected by TAN-
GO algorithm, which predicts aggregation propensities. ThisTable 1
Overview of aggregation parameters obtained from ﬁtting the measured turb
Peptide k, apparent rate of aggregation Approxima
huPrP(110–127)Ba 0.055 ± 0.017 48
huPrP(128–136)A 0.036 ± 0.003 12
huPrP(128–136)B 0.023 ± 0.003 16
huPrP(128–136)C 0.012 ± 0.003 12
Average 0.0237 13.3
huPrP(128–145)Ab n.a. 16
huPrP(128–145)B (0.32 ± 0.06) 16
huPrP(128–145)Cb n.a. 16
Average n.a. 16
huPrP(137–145)Ac n.a. n.a.
huPrP(137–145)B 0.16 ± 0.03 8
huPrP(137–145)C 0.14 ± 0.02 8
Average 0.15 8
huPrP(137–157)Ad n.a. 0
huPrP(137–157)B 0.026 ± 0.004 36
huPrP(137–157)C 0.018 ± 0.002 28
Average 0.022 32
huPrP(140–158)R151Ge 0.06 ± 0.02 101
k is the apparent rate of aggregation, tm is the calculated mid-point of the e
indicates the time before onset of the transition. taggr is tm subtracted from the
the diﬀerence between initial state and after the transition. Except for helix 1-
and C) for each peptide, which have been independently measured. Peptide
turbidimetric assay (huPrP(106–127); huPrP(110–127)A and C; huPrP(110–1
ahuPrP(110–127)B was the only sample including the alanine-rich sequence (o
applied in this study.
bNo ﬁt was possible due to extremely fast aggregation of huPrP(128–136)A
imately determined by estimation. The average was calculated from these tw
cDenotes entries for which no ﬁt was possible due to low of aggregation as
dNo ﬁt was possible for huPrP(137–158) due to a non-sigmoidal behaviour
eAggregation was only observed for the destabilized variant R151G of the papparently is due to the positive charge of the His residue at
the pH of 4.5. At higher pH, when histidine is uncharged, a
small aggregation propensity is detected by the TANGO algo-
rithm. Exchange of Tyr, which has similar steric requirements,
for His, however, results in a high calculated aggregation pro-
pensity (see Table 2A). Therefore, a comparison of several spe-
cies speciﬁc polymorphism contained in this region with
TANGO was performed on the IIYF background. Interest-
ingly, I138-I (human) and L138-I (bovine and ovine) exhibited
a comparable aggregation score in TANGO, while M138-I
(mouse) and M138-M (syrian hamster) showed a signiﬁcant
decrease in the calculated aggregation propensity, with
M138-M being the least aggregation prone sequence (see Table
2B). This might at least partially account for the diﬃculty of
experimental TSE transmission from bovine and human
sources to hamsters and mice. The exposed structural position
of the IIHF-sequence further stresses its possible importance in
the aggregation initiation and interaction between PrPC and
PrPSc (see Fig. 1). In fact, a recent study by Vanik et al.,
who used peptides corresponding to the sequences 23–144 of
man, mouse, and hamster, revealed the same order of aggrega-
tion susceptibility as suggested by TANGO. Also, cross seed-
ing experiments could demonstrate the importance of this
sequence for the species barrier [29]. Further, the IIHF-
sequence was identiﬁed as contact site between diﬀerent prion
proteins as an early step in the transconformation process in aidity curves to a sigmoid function
te lag-time (h) tm (h) taggr (h) (lag-time – tm) DA450
64 ± 2 16 0.029
31 ± 2 19 0.127
48 ± 1 32 0.105
46 ± 11 34 0.175
41.7 28.3 –
18–21 1–2 0.050
(52 ± 7) (36) 0.027
18–21 1–2 0.012
18–21 1–2 –
n.a. n.a. 0.004
15 ± 2 7 0.019
16 ± 2 8 0.017
15.5 7.5 –
n.a. n.a. n.a.
65 ± 2 33 0.045
66 ± 2 38 0.087
65.5 35.5 –
131 ± 15 30 0.034
xperimental data ﬁtted to a sigmoidal transition. The lag-time column
lag-time measuring the speed of the aggregation reaction. DA450 shows
peptides, three apparently identical samples have been prepared (A, B,
s not shown in this table exhibited no measurable aggregation in the
20); huPrP(140–158) wt and N153W).
ut of nine) that showed a transition under the experimental conditions
and C within two data points. In this case, tm and taggr were approx-
o data sets.
indicated by the small DA450.
of the data.
eptide corresponding to helix 1.
Fig. 2. Electron micrographs (left column) and CR stains (right
column) for selected peptides are shown on page 5. The black bar in
the EM pictures corresponds to 100 nm. (A) EM, huPrP(106–127); (B)
CR stain, huPrP(106–127); (C) EM, huPrP(110–127); (D) CR stain,
huPrP(110–127); (E) EM, huPrP(128–136); (F) CR stain, huPrP(128–
136); (G) EM, huPrP(137–145); (H) CR stain, huPrP(137–145).
Although peptides huPrP(106–127) and huPrP(110–127), which con-
tain the alanine-rich palindrome, did not produce observable transi-
tions in the turbidimetric assay, aggregates were formed during
prolonged incubation (panels A and C) – in contrast to huPrP(1110–
120), which never formed aggregates. Panel E, showing huPrP(128–
136), which includes the sequence of b-strand 1 that has been used as
model for the aggregation of an isolated b-structure, exhibits only very
thin ﬁbrillar aggregates. huPrP(137–145), including the IIHF-motive,
apparently forms highly ordered aggregates (panel G), which, how-
ever, display the typical golden-green birefringence expected for
amyloidogenic aggregates in CR stains (panel H).
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Daggett [30]. As pointed out earlier, the structural conversion
of PrPC to PrPSc likely involves an order-to-disorder-to-ordertransition of the sequence prior to helix 2. In view of recent re-
sult it appears likely that aggregation actually starts from par-
tially disordered states [31,32], which are present even under
equilibrium conditions [33–35]. It has been shown that se-
quences with neighbouring large, hydrophobic amino acids fa-
vour extended, b-like conformations even under strongly
denaturing conditions [20]. Thus, even in the disordered state,
I138-IHF is likely to populated sheet-like conformations due
to intrinsic amino acid properties. Indeed, such a conforma-
tional preference could be detected in peptide models [27].
Therefore, I138-IHF can serve as an aggregation site either
for homo- or for hetero-sequence aggregation, e.g., with the
alanine-rich sequence [30].3.2. Helix 1 has no tendency to form aggregates, it can delay but
not prevent ﬁbril formation in longer peptides
Further sigmoidal transitions could be observed for peptides
huPrP(128–145), huPrP(137–145) and huPrP(137–157),
although the diﬀerences in absorbance were less pronounced,
which may be related to diﬀerences in morphology and size be-
tween peptide aggregates. In contrast to the abovementioned
peptides, peptides consisting solely of helix 1 (huPrP(140–
158) and its stabilized variant N153W), excluding the ﬂanking
sequences, showed no aggregation tendency whatsoever. Only
a destabilized variant, huPrP(140–158)-R151G, showed a very
slow, shallow transition which could be observed after 101 h
(see Table 1). Here, the intense network of salt-bridges and
favourable electrostatic interactions within helix 1 is distorted,
obviously enabling aggregation, presumably by interaction of
aromatic residues.
However, adding the sequence of helix 1 to strongly aggre-
gating peptides like huPrP(128–145) did not abolish ﬁbril for-
mation, but nevertheless delayed the formation of aggregates
to an average lag-time of 30 h for huPrP(137–157), compared
to 8 h for huPrP(137–145), and 16 h for huPrP(128–145),
which is approximately of the same length. The growth phase
of aggregates measured by taggr, however, is much longer (see
Table 1).
This leads to the possibility that helix 1 might remain in a
helical conformation during the early stages of the transcon-
formation process. This is again supported by the study of
molecular dynamics data recently published by DeMarco
and Daggett, which showed no conversion of helix 1 during
the simulated protoﬁbril formation [30]. Later in the course
of the conformational transition, facilitated by conformational
changes in its surroundings, the energetically unfavourable
conversion of helix 1 into an extended structure could take
place. This is in line with studies showing the existence of heli-
cal PrP dimers in the early stages of the SDS induced prion
transconformation, which later form higher oligomers rich in
b-sheet elements [36]. As previously hypothesized [27], helix 1
might play the role of a ‘‘gatekeeper’’ element in the aggrega-
tion process, by acting as an energetic barrier for the transcon-
formation of PrP.3.3. The alanine-rich sequence requires ﬂanking parts of the
sequence to form ﬁbrillar aggregates
The palindromic alanine-rich sequence A113-GAAAGA is
believed to be causal for neuro-inﬂammation induced by the
peptide PrP(106–126). Interestingly, huPrP(106–126) did not
show an observable transition that would indicate aggregate
Table 2
Summary of TANGO calculations
A S132-AMSRP-IIHF-GSDY-E146
Wt–pH 4.5 Wt–pH 8.5 P137V H140A H140Y
0.0% 0.5% 0.9% 17.3% 47.8%
B S132-AMSRP-[II][LI][MI][MM]-YFGSDY-E146
–IIHF– (human) –LIHF– (bovine/sheep) –MIHF– (mouse) –MMHF– (hamster)
47.8% 31.4% 8.8% 0.9%
C A113-AGAAAAGAVVGGLGGYML-G131
Wt A117V G119A M129V
A113ﬁ G131 1.1% 9.4% 7.1% 2.5%
A113ﬁ A120- 0.9% 10.6% 7.3% 0.9%
-V121–V122- 2.2% 17.2% 13.5% 4.0%
-G123ﬁ G131 0.2% 0.5% 0.5% 2.6 %
A – Aggregation propensity of the IIHF-region: inﬂuence of the charge pattern on aggregation propensities. B – Eﬀects of species speciﬁc sequence
variations: I138 and I139 vary considerably among species and have a strong eﬀect on the aggregation propensity (Note. Variant H140Y has been
used to estimate species speciﬁc eﬀects; see panel A). C – Inﬂuence of single residue substitutions on the aggregation propensities of the sequence
huPrP(113–131) and selected sub-sequences (huPrP(A113–A120), huPrP(V121–V122), and huPrP(G123–G131), which includes b-strand 1). It shall
2038 J. Ziegler et al. / FEBS Letters 580 (2006) 2033–2040formation within 180 h under our conditions.2 The same holds
true for huPrP(110–120), which contains almost exclusively the
alanine-rich region, and for huPrP(120–127), which contains
additional hydrophobic residues. Prolonged incubation of
huPrp(106–127) and huPrP(110–127) ﬁnally leads to aggregate
formation. The aggregates of huPrP(106–127) exhibit a typical
ﬁbrillar morphology in the ER, almost resembling a disordered
arrangement of protoﬁbrils, whereas huPrP(110–127) forms
amorphous aggregates (see Fig. 2). Regardless of the morphol-
ogy, in both cases the aggregates showed the typical red-green
birefringence in a CR stain, indicating the presence of amyloid
(see Fig. 2). However, it was not possible to perform CR-stain-
ing nor to detect aggregates in EM-micrographs for
huPrP(110–120).
These results are somewhat surprising, as several other stud-
ies implicated the apolar palindromic sequence AGAAAAGA
in ﬁbril formation and cytotoxicity of peptides around the
110–120 region [12,37,38]. Nevertheless, our data do not con-
tradict the importance of the palindromic sequence for the
conformational transition of PrP. Molecular dynamics studies
showed the importance of a template for the re-folding of this
sequence [30], whereas our studies only tested for auto-aggre-
gation within the same sequence. In particular, protoﬁbril
models derived from such simulations showed a b-core made
up from residues 116–119, adding as a third strand to the na-
tive b-sheet, the elongated native sheet itself and another
strand containing residues 135–140, underlining the impor-
tance of I138-IHF for the pathogenic process. Importantly, in-
ter-prion contacts in this model are formed between residues
116–119 (alanine-rich) and residues 135–140, corresponding
to the above proposed IIH(F) aggregation site.
Extending the 110–126 peptide on the amino terminal side to
form huPrP(106–126), however, restores the alanine-rich pep-
tide’s (huPrP(110–120)) ability to form amyloid-like ﬁbrillar
plaques (see Fig. 2). This points to a role of the 106–110 region2 NB: Transitions of alanine-rich peptides could be observed within
the observation periode at higher concentrations in this study as well as
under other experimental conditions in other studies.as another possible initiator site, which is further underscored
by the importance of the 90–112 region for prion infectivity
[39]. So, while the palindromic region might not be able to
form amyloid ﬁbrils by itself, it may be included into ﬁbrillar
structures, whose formation is initiated by other regions of
the peptide. Further evidence for this behaviour could be
found in TANGO calculations of aggregation propensities
(see Table 2C). The isolated AGAAAAGA showed a low
TANGO score due to the presence of ﬂexibility increasing
Gly residues [20], which have also been shown to be evolution-
ary conserved in order to prevent aggregation in other cases
[40]. However, elongation of the sequence to AGAAAA-
GAVV, as well as the introduction of the pathogenic A117V
mutation [41] increased the calculated aggregation tendency
of the peptide indicating that the aggregation propensity is
introduced by the valine residues. An explanation for this
behaviour can be found in the conformational propensity of
the palindromic region. Conformationally ﬂexible, short Ala-
rich peptides are known to preferentially populate polyproline
type II-like conformations, which are close to extended con-
formers in the Ramachandran space [42]. The presence of
rather bulky Val residues, however, might shift the conforma-
tional distribution in the direction of b-sheets [43]. The propen-
sity for poly-proline II (PPII) like conformations also oﬀers an
explanation for the need for a template in the aggregation pro-
cess, as PPII helices show an intrinsic tendency to interact and
form coiled-coils, such as in collagen. Proline rich peptides,
such as iPrP13 (DAPAAPAGPAVPV), which has been de-
signed to inhibit aggregation into b-sheets [44], could therefore
present an ideal template. Indeed Soto et al. could show that
iPrP13 interacts with the AGAAAAGA palindrome and inter-
feres with the prion transconformation – possibly by present-
ing a stronger interacting template for the palindrome than
natural interaction partners like I138-IHF. Further experimen-
tal evidence can be deduced from the work of Chabry et al.,
who found that peptides encompassing the palindromic region
(113–141, 115–141, 117–141 and 119–141) could inhibit the
conversion of full length prion protein in a dosis-dependent
manner, while the only marginally shorter peptide 121–141
showed no inhibitory eﬀect [45].
J. Ziegler et al. / FEBS Letters 580 (2006) 2033–2040 2039In summary, our study results in two major ﬁndings, namely
that the bulky, apolar, and highly surface-exposed I138-IHF se-
quence is a possible initiation site for aggregation and that the
aggregation properties of the neurotoxic peptide huPrP(106–
126) are centred at residues 106–110 and VV(121–122), respec-
tively. Recent molecular dynamics simulations of the PrPC to
PrPSc conversion [30] as well as studies concerning the species
barrier [29] also point to the importance of those regions in
the aggregation initiation process. The crucial role of these
structural elements is further underscored by the existence of
several pathogenic mutations. Our TANGO calculations indi-
cate that the importantM129V polymorphism, which is located
in b-strand 1 and is responsible for phenotypic heterogeneity of
prion diseases [46] and susceptibility for the classical and new
variant Creutzfeldt-Jakob Disease (CJD) [47], changes the
aggregation propensity in the VV(121–122) region. In addition,
the Gerstmann–Stra¨ussler–Scheinker syndrome (GSS)-causing
G131V mutation, also located in b-strand 1, could be shown to
increase local conformational plasticity, thereby facilitating
prion transconformation [47]. Thus, if b-strand 1 becomes ex-
posed during structural rearrangements, it may also eﬃciently
enhance aggregation as shown here. The only amyloidogenic
element described here which does not harbor any pathogenic
mutations is the I138-IHF sequence. However, the diﬀerences
in sequence between various species suggest a role of this region
in the species barrier. We have shown that IIHF has the ability
to aggregate fast compared to, e.g., b-strand 1. With b-strand 1
being hidden in PrPC, this makes the partially surface-exposed
I138-IHF motive the most important identiﬁed aggregation
promoting element in PrP. In combination with recent data
from the literature a concerted operation of several amyloido-
genic elements appears a likely mechanism in formation of in-
ter-prion protein contacts. Interaction of diﬀerent elements
may also explain the conformational heterogeneity observed
in prion strains.
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